scholarly journals Serum levels of heat shock protein 27 in patients with acute ischemic stroke

2013 ◽  
Vol 18 (4) ◽  
pp. 531-533 ◽  
Author(s):  
Gabriella Gruden ◽  
Federica Barutta ◽  
Irene Catto ◽  
Giovanni Bosco ◽  
Maria Giovanna Caprioli ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Acute Ischemic Stroke ◽  
Serum Levels ◽  
Heat Shock Protein 27

scholarly journals Serum levels of anti-heat shock protein 27 antibodies in patients with chronic liver disease

2020 ◽  
Vol 26 (1) ◽  
pp. 151-157
Author(s):  
Gabriella Gruden ◽  
Patrizia Carucci ◽  
Federica Barutta ◽  
Davina Burt ◽  
Arianna Ferro ◽  
...  
Keyword(s):  
Liver Disease ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Heat Shock Protein 27 ◽  
Chronic Liver

scholarly journals Heat Shock Protein 27 (HSP27) As a Therapeutic Target in Ischemic Stroke and Neurodegenerative Disorders

2017 ◽  
Vol 63 (1) ◽  
pp. 17-21 ◽  
Author(s):  
HIDEKI SHIMURA ◽  
RYOTA TANAKA ◽  
TAKAO URABE ◽  
NOBUTAKA HATTORI
Keyword(s):  
Ischemic Stroke ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Neurodegenerative Disorders ◽  
Therapeutic Target ◽  
Heat Shock Protein 27

scholarly journals Blood Pressure and Heat Shock Protein 70 Levels Related to Acute Ischemic Stroke Severity

2020 ◽  
Vol 2 (2) ◽  
pp. 49-55
Author(s):  
Syarif Indra ◽  
Umul Khair ◽  
Yulia Trisna
Keyword(s):  
Blood Pressure ◽  
Ischemic Stroke ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Acute Ischemic Stroke ◽  
P Value ◽  
Stroke Severity ◽  
Hsp 70 ◽  
Cross Sectional ◽  
Significant Difference

Introduction: Hypertension is a risk factor of ischemic stroke, the prevalence of ischemic stroke in Indonesia is 34.1%. Heat Shock Protein (HSP) 70 increases in hypertension and acute phase of ischemic stroke. To determine differences of blood pressure (BP) and HSP 70 levels, related to the acute ischemic stroke severity. Methods: This was a cross-sectional study that was carried out in the Neurological Ward of Dr.M.Djamil Hospital and National Stroke Hospital, from May to September 2019. Inclusion criteria were obtained consecutively. BP was measured with a sphygmomanometer, stroke severity was measured by NIHSS, and HSP 70 levels was analyzed by the ELISA. Computerized statistical analyzes were performed using SPSS software version 23.0 for windows. The result was statistically significant if the p-value < 0.05. Results: There were 40 samples consisted of 26 (65%) male, mean age 59.78 years. The systolic BP ranging from 130 to 190 mmHg (median 160), the diastolic BP ranging from 70 to 100 mmHg (median 90), the HSP 70 levels ranging from 2.50 to 19.56 ng/mL (median 2.72). There were 18 patients with mild stroke and 22 patients with moderate stroke. There was no significant difference between systolic blood pressure (SBP), diastolic blood pressure (DBP), and severity of stroke (p=0,369; p=0,221, respectively). There was no significant difference between HSP 70 levels and the severity of stroke (p=0,312). There was no relation between the degree of BP and HSP 70 levels. Conclusion: There were no significant differences of SBP, DBP, and HSP 70 with the acute ischemic stroke severity.

Heat shock protein 27 as a neuroprotective biomarker and a suitable target for stem cell therapy and pharmacotherapy in ischemic stroke

2019 ◽  
Vol 44 (2) ◽  
pp. 356-367 ◽  
Author(s):  
Marjan Behdarvandy ◽  
Mohammad Karimian ◽  
Mohammad Ali Atlasi ◽  
Abolfazl Azami Tameh
Keyword(s):  
Stem Cell ◽  
Ischemic Stroke ◽  
Heat Shock ◽  
Cell Therapy ◽  
Heat Shock Protein ◽  
Stem Cell Therapy ◽  
Heat Shock Protein 27 ◽  
Suitable Target

Transient Hypoxia Leads to Increased Serum Levels of Heat Shock Protein-27, -70 and Caspase-Cleaved Cytokeratin 18

2014 ◽  
Vol 60 (02/2014) ◽  
Author(s):  
Michael Lichtenauer ◽  
Matthias Zimmermann ◽  
Stefanie Nickl ◽  
Alexander Lauten ◽  
Bjoern Goebel ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Protein ◽  
Serum Levels ◽  
Heat Shock Protein 27 ◽  
Cytokeratin 18

scholarly journals Heat Shock Proteins 27 and 60 Serum Levels in Patients with Gastrointestinal Cancer and Acute Myocardial Infarction in Birjand, Iran

2018 ◽  
Vol 3 (2) ◽  
pp. 75
Author(s):  
Seyedyoosef Javadmoossavi ◽  
Maryam Moosavi ◽  
Tooba Kazemi ◽  
Arash Ghorbani Abdi Saedabad ◽  
Tahmine Tavakoli ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Serum Levels ◽  
Heat Shock Protein 27 ◽  
Heat Shock Protein 60 ◽  
Healthy Individuals ◽  
Patients With Cancer ◽  
The Mean ◽  
Shock Proteins

Introduction: Cancer and myocardial infarction are lethal diseases. Their prevalence is increasing worldwide. In both diseases, the level of oxidative stress rises because of tissue damage. The aim of this study was to evaluate the serum levels of heat shock protein 27 and heat shock protein 60 in patients with cancer and myocardial infarction, and then compare them with healthy individuals.Materials and Methods: After blood samples were collected from the participants, plasma and serum were separated from these samples for further examination. The serum levels of heat shock protein 27 and heat shock protein 60 were measured with related kits in 30 patients with cancer and 30 patients with acute myocardial infarction, followed by 30 healthy individuals. The collected data were then analyzed in the Statistical Package for the Social Sciences software (version 22).Results: The mean serum levels of heat shock protein 27 in cancer patients (25.21 ± 5.57 ng/mL) and in patients with myocardial infarction (45.23 ± 7.43) were significantly higher than those in healthy individuals (10.61 ± 3.11; P<.05). In addition, the mean serum levels of heat shock protein 60 in patients with cancer (19.23 ± 3.41 ng/mL) and patients with myocardial infarction (22.23 ± 2.25 ng/mL) were significantly higher than those in healthy individuals (8.38 ± 2.53; P<.05).Conclusion: An increase in the serum levels of heat shock proteins 27 and 60 was observed in patients with cancer and myocardial infarction. Therefore, we can suggest that these biomarkers should help surgeons or physicians to diagnose the diseases.

scholarly journals HEAT SHOCK PROTEIN 27 IN LARYNGEAL SQUAMOUS CELL CANCER TREATMENT

2020 ◽  
Vol 46 (3) ◽  
Author(s):  
O. V. Horolec ◽  
V. A. Kashirin ◽  
L. L. Voroncova
Keyword(s):  
Heat Shock ◽  
Heat Shock Protein ◽  
Cancer Patients ◽  
Laryngeal Cancer ◽  
Cell Cancer ◽  
Serum Levels ◽  
Heat Shock Protein 27 ◽  
Test System ◽  
Special Treatment ◽  
Cell Physiology

Abstract Heat shock protein 27 (HSP27) belongs to a family of ATP-independent chaperones and plays a fundamental role in cell physiology in various disease states, including cancer. So, it was found that serum HSP27 levels were significantly increased in patients with various tumors, but their significance in laryngeal carcinoma is not well defined. Purpose of the study. Determination and comparison HSP27 serum levels at different stages of special treatment methods in laryngeal cancer patients. Materials and methods. The studies were conducted in 31 patients of laryngeal cancer of T2–3 N0 M0 categories before treatment and at its various stages. The serum HSP27 levels analysis was carried out using the «ELISA» diagnostics test system by enzyme immunoassay. Results. The serum HSP27 levels in patients before treatment and with various types of special treatment are statistically significantly higher than the control values. There was a decrease in serum HSP27 levels in patients after removal of the neoplasm and a slight increase in serum HSP27 levels after completion of radiation therapy. Comparison of initial serum HSP27 values in patients with subsequent relapse of the disease with initial serum HSP27 levels in patients with positive treatment outcomes did not reveal statistically significant differences. Conclusion. The serum HSP27 levels in laryngeal cancer patients are elevated and remain so at all treatment stages. Initial level of serum HSP27 cannot predict tumor recurrence. Keywords: laryngeal cancer, HSP27.

scholarly journals Endothelium-targeted overexpression of heat shock protein 27 ameliorates blood–brain barrier disruption after ischemic brain injury

2017 ◽  
Vol 114 (7) ◽  
pp. E1243-E1252 ◽  
Author(s):  
Yejie Shi ◽  
Xiaoyan Jiang ◽  
Lili Zhang ◽  
Hongjian Pu ◽  
Xiaoming Hu ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Brain Injury ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Blood Brain Barrier ◽  
Actin Polymerization ◽  
Heat Shock Protein 27 ◽  
Brain Barrier ◽  
Blood Brain ◽  
Neurological Conditions

The damage borne by the endothelial cells (ECs) forming the blood–brain barrier (BBB) during ischemic stroke and other neurological conditions disrupts the structure and function of the neurovascular unit and contributes to poor patient outcomes. We recently reported that structural aberrations in brain microvascular ECs—namely, uncontrolled actin polymerization and subsequent disassembly of junctional proteins, are a possible cause of the early onset BBB breach that arises within 30–60 min of reperfusion after transient focal ischemia. Here, we investigated the role of heat shock protein 27 (HSP27) as a direct inhibitor of actin polymerization and protectant against BBB disruption after ischemia/reperfusion (I/R). Using in vivo and in vitro models, we found that targeted overexpression of HSP27 specifically within ECs—but not within neurons—ameliorated BBB impairment 1–24 h after I/R. Mechanistically, HSP27 suppressed I/R-induced aberrant actin polymerization, stress fiber formation, and junctional protein translocation in brain microvascular ECs, independent of its protective actions against cell death. By preserving BBB integrity after I/R, EC-targeted HSP27 overexpression attenuated the infiltration of potentially destructive neutrophils and macrophages into brain parenchyma, thereby improving long-term stroke outcome. Notably, early poststroke administration of HSP27 attached to a cell-penetrating transduction domain (TAT-HSP27) rapidly elevated HSP27 levels in brain microvessels and ameliorated I/R-induced BBB disruption and subsequent neurological deficits. Thus, the present study demonstrates that HSP27 can function at the EC level to preserve BBB integrity after I/R brain injury. HSP27 may be a therapeutic agent for ischemic stroke and other neurological conditions involving BBB breakdown.

Sign in / Sign up

Export Citation Format

Share Document